Hepatorenal Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Hepatorenal syndrome (HRS) is a multiorgan condition affecting both the kidneys and the liver, primarily observed in individuals with acute or chronic liver disease. The incidence of HRS in patients with decompensated liver disease is about 4%, with most cases being associated with conditions like alcoholic hepatitis, cirrhosis, or metastatic cancers leading to portal hypertension. The likelihood of HRS development reaches 18% at one year and 39% at five years in these patients, particularly those with hyponatremia and high plasma renin activity. Spontaneous bacterial peritonitis can contribute to HRS in one-third of cases. The key triggers for HRS include spontaneous bacterial peritonitis, large-volume ascites paracentesis without plasma expansion, and gastrointestinal bleeding. Any form of sepsis can provoke HRS in cirrhosis patients due to the release of sepsis-related vasoactive mediators, similar to those in portal hypertension. Liver transplantation is the definitive treatment offering the best long-term survival prospects. Prognosis varies for different types of HRS; Type 1 HRS is associated with poor survival, averaging less than two weeks. Type 2 HRS survival depends on the severity of the Child-Pugh class of liver disease, typically ranging from 6 to 12 months without treatment. HRS is estimated to occur in approximately 8-10% of individuals with ascites and cirrhosis.

 

Thelansis’s “Hepatorenal Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hepatorenal Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Hepatorenal Syndrome across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hepatorenal Syndrome Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Hepatorenal Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Hepatorenal Syndrome, Hepatorenal Syndrome market outlook, Hepatorenal Syndrome competitive landscape, Hepatorenal Syndrome market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)